NCT07001904

Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.

Detailed description

Psoriasis is a chronic, immune-mediated inflammatory dermatological condition that impacts around 0.2% to 4.8% of the worldwide population. Interleukin (IL)-6 is a pleiotropic cytokine that regulates immunity, hematopoiesis, and inflammation. It is produced by keratinocytes, endothelial cells, fibroblasts, and immune cells like macrophages and dendritic cells. Increased IL-6 expression has been observed in psoriatic lesions, suggesting its involvement in disease pathogenesis

Conditions

• Interleukin-6
• Plaque Psoriasis
• Disease Severity

Interventions

Type	Name	Description
OTHER	Enzyme-linked immunosorbent assay (ELISA)	The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum

Timeline

• Start date: 2023-11-01
• Primary completion: 2024-10-31
• Completion: 2024-10-31
• First posted: 2025-06-03
• Last updated: 2025-06-03

Locations

1 site across 1 country: Egypt